Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday

Theravance Biopharma (NASDAQ:TBPH) will be issuing its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $8.94 on Friday. The firm has a market capitalization of $437.36 million, a price-to-earnings ratio of -9.72 and a beta of 0.25. The stock’s 50-day simple moving average is $8.29 and its 200-day simple moving average is $8.69. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $11.71.

Analyst Ratings Changes

Several research firms have recently commented on TBPH. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. TD Cowen cut their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Finally, Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.